Company Profile

Lypro Biosciences Inc
Profile last edited on: 3/22/18      CAGE: 4LSA8      UEI:

Business Identifier: Nanoscale particles bound by high density lipoprotein to improve drug delivery
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

Catalina Avenue
Alameda, CA 94502
   (510) 748-9100
Location: Single
Congr. District: 13
County: Alameda

Public Profile

In November 2017, it was announced that Lyrpro Biosciences had been acquired by Cerenis Therapeutics and will operate as a subsiduary to that entitity. Lypro Biosciences Inc is a biotechnology venture initially grounded in research activities conducted at Children’s Hospital Oakland Research Institute and University of California, San Francisco. The firm is a specialty biopharma company whose technology addresses the adverse effects arising from the insoluble nature of certain hydrophobic drugs. Lypro’s proprietary technology is based on lipid-based targetable, self-assembling, Nanodisks™. Incorporating drugs into the highly stable and water-soluble Nanodisks™ holds the promise of increased efficacy, lower doses, and reduced incidence and severity of side effects compared to current formulations. Lypro Biosciences has proof-of-concept data with Amphotericin-B, a highly effective, but highly toxic system fungal drug, in which the Lypro NanoDisks outperform both the native form of the drug and a liposomal formulation in efficacy and/or toxicity. Lypro’s pipeline includes NanoDisks loaded with off-patent compounds, targeted compounds and research reagents. The firm has programs underway in cancer, infectious diseases, imaging and neurosciences. The NanoDisk technology has been applied to the agricultur

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 2 NIH $2,399,281
Project Title: Inhalable amphotericin B nanodisk therapy for pulmonary aspergillosis
2009 1 NIH $109,354
Project Title: Nanobiotechnology For The Treatment Of Mantle Cell Lymphoma

Key People / Management

  Murray Brozinsky -- Founder and President

  Michelle Stecklein Call -- CEO

  Stephen F Carroll -- Director of Discovery & Development

  Trudy M Forte

  Michael Oda -- Founder

  Robert O Ryan -- Founder, Chief Scientific Officer

  Dung L Thai

  Stuart Wren -- Business Development:

Company News

There are no news available.